Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Mary Carroll

Internal Medicine Rosedale, MD Medical Doctor

NPI 1730153636 CMS profile 498218

9110 Philadelphia Rd., Ste. 108, Rosedale, MD 21237

Open in the dashboard

General payments

$2,148

145 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Mary Carroll of Rosedale, MD is reported in the CMS Open Payments database as having received $2,148 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $271 17
2021 General $390 29
2020 General $548 40
2019 General $939 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Carroll
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mary Carroll were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mary Carroll Internal Medicine median Middle half National median
2019 $939 $159 $48–$570 $163
2020 $548 $119 $33–$402 $114
2021 $390 $135 $37–$521 $132
2022 $271 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Lilly USA, LLC $520 34 payments
  2. AstraZeneca Pharmaceuticals LP $462 24 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $383 23 payments
  4. Novo Nordisk Inc $343 36 payments
  5. Pfizer Inc. $108 8 payments
  6. E.R. Squibb & Sons, L.L.C. $90 6 payments
  7. AbbVie, Inc. $63 3 payments
  8. Abbott Laboratories $44 2 payments
  9. Merck Sharp & Dohme Corporation $37 3 payments
  10. Novartis Pharmaceuticals Corporation $36 2 payments
  11. Other $62 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,128 143 payments
  2. Education $20 2 payments
Products named General payments · program years 2019–2022
  1. TRULICITY $475 30 payments
  2. JARDIANCE Diabetes $437 27 payments
  3. FARXIGA $434 22 payments
  4. Ozempic $329 35 payments
  5. RYBELSUS $310 32 payments
  6. JARDIANCE Diabetes $284 15 payments
  7. BASAGLAR $267 16 payments
  8. SYMBICORT $148 1 payment
  9. PULMICORT RESPULES $148 1 payment
  10. GLYXAMBI $105 5 payments
  11. Other $883 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Internal Medicine: 777

Drug cost

$812

Median for Internal Medicine: $73,373

Branded share of claims

100%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ultra-Fine Nano Pen Needle Pen Needle, Diabetic Brand 14 $812

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record